October 2025

Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.

FDA accelerated approval speeds access but faces challenges with trial completion, costs, and end point validation.

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.

Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

Explore the profound connection between emotions and oncology pharmacy, highlighting the importance of acknowledging feelings in patient care.

Explore how targeted therapies and immunotherapies transform oncology, highlighting novel antibody treatments and their impact on patient care and outcomes.